Authors
Latest:
Turning Detailed Drug Profiles into Targeted Business InsightsHaving invested heavily in new regulatory database systems, life sciences firms owe it to themselves to capitalize on the insights locked within those rich data assets, writes David Gwyn.
Latest:
Large Pharma Tries New Approach to Non-AdherenceMedication non-adherence is a real problem, this article looks at how to help patients better control their treatments and improve adherence.
Latest:
Digital Drives Customer-Centric Sales EngagementHow digital is helping companies increase call volumes, access to HCPs, and HCP-led dialogue.
Latest:
Preparing for Competitive Challenges to Biologics with Expiring Market ExclusivityGuidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.
Latest:
Preparing for Competitive Challenges to Biologics with Expiring Market ExclusivityGuidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.
Latest:
Practically Speaking: Driving Clinical TransformationThis video series discusses the impact of implementing risk-based quality management (RBQM) and decentralized clinical trials (DCTs) from the clinical operations point of view.
Latest:
The 5 Safes of Risk-Based AnonymizationBefore you can leverage sensitive data for secondary uses – such as Real-World evidence (RWE) analysis – you have to make it safe. The 5 Safes of Risk-Based Anonymization will help you properly measure and manage risk, establishing a balance between protecting individual identity and optimizing data utility. Live: Wednesday, Feb. 26, 2020 at 10am EST | 9am CST | 3pm GMT | 4pm CET On demand available after airing until Feb. 26, 2021. Register free
Latest:
The 5 Safes of Risk-Based AnonymizationBefore you can leverage sensitive data for secondary uses – such as Real-World evidence (RWE) analysis – you have to make it safe. The 5 Safes of Risk-Based Anonymization will help you properly measure and manage risk, establishing a balance between protecting individual identity and optimizing data utility. Live: Wednesday, Feb. 26, 2020 at 10am EST | 9am CST | 3pm GMT | 4pm CET On demand available after airing until Feb. 26, 2021. Register free
Latest:
The Roots and Rise of Cell and Gene TherapyContinued investment will mean new cures in a new decade.
Latest:
The Roots and Rise of Cell and Gene TherapyContinued investment will mean new cures in a new decade.
Latest:
Using Service to Drive Commercial ValueOne ‘team’ model’s advantages in brand outreach and awareness.
Latest:
Connecting and Leveraging Quality-Driven DataMasterControl’s new e-book proves how the adoption of a data-driven and technology-supported approach to product life cycle management differentiates pharma leaders.
Latest:
China: Recruiting Talent Amid the Corruption FalloutThe GSK bribery investigations in China has given recruiters pause for thought. Gregory Lovas offers some do's and don'ts for keeping your emerging market recruitment drive on track.
Latest:
Education: The Creative DifferentiatorEverything has an MOA. Bourbon has an MOA. There’s nothing unique about that. What’s differentiating is the benefit associated with the molecule’s MOA.
Latest:
2020 and Beyond Will Bring Significant Progress in Addressing Mental IllnessProgress has been made in developing new approaches for patients with serious mental health conditions.
Latest:
Critical Connection: Patient Services and Product LaunchA look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Latest:
Critical Connection: Patient Services and Product LaunchA look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Latest:
Prescribing Patterns: How to Get Ahead of the TrendsThe key to success in a hypercompetitive marketplace is to create targeting plans that get ahead of tomorrow’s prescriptions.
Latest:
Towards a Multichannel Marketing CultureThe biggest challenge to becoming a multi-channel marketing organization is not a company's technology, it’s the culture, write Melissa Dimitri, Larry Smith, Laurel Fitts, and Mark Trybulski.
Latest:
The Brexit Deal and the Life Sciences SectorOn December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.
Latest:
Transforming the CIO Role to Embrace Digital HealthStrategies for those chief information officers taking the digital reins at their organizations.
Latest:
Forget Selecting a Site — Now the Site Selects YouPost-approval studies, at many companies, do not have a consistent strategy that builds networks of investigators.
Latest:
Commercializing an Orphan Drug: Why “Just” Serving a High Unmet Medical Need Won’t Do the JobLooking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug
Latest:
A Contingent Workforce Strategy Is Critical to Life Sciences CompaniesSpeed to market is crucial to the success of launching new products and therapies.
Latest:
How Tariffs will Impact Localized ProductionArda Ural discusses the possible impact on how companies plan for growth based on the impact of the tariffs.
Latest:
How UCB Transformed into a More Agile, Data-Driven OrganizationAnita Moser, Michael Davis, Dharmendra Sahay outline UCB's measured approach to scaling its AI capabilities.
Latest:
Lean Thinking in Life Sciences: A Case for Enabling PeopleFully understanding the construct of what it means to be lean can equip individual contributors, teams, and leaders to contribute to the fullest extent of their capabilities.
Latest:
What You Need to Know about the Drug Supply Chain Security ActIt is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.
